Mark Ragosa
Director of Finance/CFO chez KINIKSA PHARMACEUTICALS, LTD.
Fortune : 370 352 $ au 31/03/2024
Profil
Mark Ragosa is currently the Chief Financial Officer & Director at Kiniksa Pharmaceuticals Corp.
He also holds the position of Chief Financial Officer & Senior Vice President at Kiniksa Pharmaceuticals Ltd.
Mr. Ragosa previously worked as the Director-Investor Relations at Ironwood Pharmaceuticals, Inc. and as a Vice President in the Equities Division at Goldman Sachs & Co. LLC.
He completed his undergraduate degree at Bowdoin College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/04/2024 | 18 771 ( 0,05% ) | 370 352 $ | 31/03/2024 |
Postes actifs de Mark Ragosa
| Sociétés | Poste | Début |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Director of Finance/CFO | 17/12/2020 |
Kiniksa Pharmaceuticals Corp.
 Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The private company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Director of Finance/CFO | - |
Anciens postes connus de Mark Ragosa
| Sociétés | Poste | Fin |
|---|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Investor Relations Contact | 01/05/2018 |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Corporate Officer/Principal | - |
Formation de Mark Ragosa
| Bowdoin College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Kiniksa Pharmaceuticals Corp.
Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The private company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Health Technology |
